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Summary Overexpression of cyclin Dl is frequently found in various types of human tumours and results
from clonal rearrangement and/or amplification involving chromosomal region 1 1q13. In order to evaluate the
pathological relevance of cyclin DI overexpression in human breast cancer, we generated a polyclonal
antiserum against the carboxy-terminal part of the cyclin DI protein. After affinity purification, the antiserum
specifically detected overexpression of cyclin DI in formalin-fixed, paraffin-embedded tumour material also.
The intensity of the nuclear stainings was, in generai, proportional to the degree ofcyclin DI amplification. We
did not encounter significant variability of staining within individual tumours with overexpression ofcyclin Dl.
Overexpression ofcyclin DI appeared to be associated with oestrogen receptor-positive breast tumours, but not
with any other clinicopathological parameter tested. Overexpression of cyclin Dl was not of prognostic value
for recurrence or survival in a consecutive series of 248 operable breast cancer patients (stage I and II).
Overexpression of p53 was also not of prognostic significance in this series, but was associated with
undifferentiated histology and oestrogen receptor-negative breast tumours, as has been reported previously by
others. A high proportion of breast tumours with a low grade of malignancy in this series of operable breast
cancer patients may explain discrepancies concerning the prognostic value of amplification and of
overexpression of cyclin Dl.
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Molecular biological research over the past several years has
led to the identification of alterations in many different proto-
oncogenes and tumour-suppressor genes, which in various
combinations contribute to the development of tumours
(Bishop, 1987). Most of these studies have attempted to relate
genetic alterations with clinical parameters. Mutation of p53,
for instance, is more frequent in the more advanced stages of
colon cancer than in early lesions, suggesting a late role in
tumour progression (Vogelstein et al., 1988). The transitions
from benign to malignant phenotype are clearly recognisable
in colon cancer, where adenomas represent the benign lesion,
from which invasive carcinomas develop via increasing
degrees of dysplasia (Sugarbaker et al., 1985). Such clear
transition stages cannot be distinguished in breast tumours.
Moreover, breast cancers are a heterogeneous group of
diseases, both in morphology and in behaviour. Therefore,
molecular biological studies in breast cancer have to rely on
prognosis, associating genetic changes with follow-up
(disease-free survival period), using long-term follow-up and
large patient series to overcome heterogeneity effects. To
evaluate such an association in breast cancer, we investigated
a series of 248 consecutive patients treated in our clinic for
operable breast cancer between 1979 and 1982. We followed
these patients for an average period of 10 years and
investigated associations of disease-free interval and clinico-
pathological parameters, among which overexpression of
cyclin Dl and p53. Overexpression of cyclin Dl was
previously found to be associated with poor prognosis
(Borg et al., 1991; Henry et al., 1993; Schuuring et al.,
1992a; Tsuda et al., 1989). Rearrangements involving cyclin
Dl were found in many different tumour types, such as
carcinomas of the breast, oesophagus, stomach, bladder and
liver, and in squamous carcinomas of the head and neck (for
reviews, see Lammie and Peters, 1991; Motokura and
Arnold, 1993). Deregulation of other cyclins has also been
detected in tumours, but deregulation of cyclin Dl appeared
to be of singular importance in the multistep process of
oncogenesis (Keyomarsi and Pardee, 1993).
In normal cells, cyclin Dl protein forms a multimer
complex with cyclin-dependent kinase, which regulates
transition through the GI phase of the cell cycle (Sherr,
1993). Overexpression of cyclin Dl either by transfection of
cyclin Dl in fibroblast cells, or in target tissues of cyclin Dl-
transgenic mice, resulted in transformation only in conjunc-
tion with other activated oncogenes, such as EIA, myc or ras.
This suggests a cooperativity in transformation between
overexpression of cyclin Dl and other oncogenes (Bodrug
et al., 1994; Hinds et al., 1994; Wang et al., 1994).
Overexpression of cyclin DI rendered growth of normal
cells less dependent on growth factors, and shortened the GI
phase of the cell cycle (Quelle et al., 1993).
The other oncogene alteration examined in this study is
alteration of the p53 tumour-suppressor gene, which occurs
in about 60% of human cancers. In combination with a
reduction in homozygosity this results in the complete loss of
the wild-type allele (Harris and Holstein, 1993; Levine et al.,
1994). The majority of p53 mutations found in human
tumours are missense mutations, usually altering protein
conformation and causing nuclear accumulation of p53,
which can be demonstrated by immunohistochemistry
(Harris and Holstein, 1993). Mutation of p53 appears to be
associated with a more undifferentiated phenotype (Marchetti
et al., 1993), is maintained throughout breast cancer
progression (Davidoff et al., 1991) and has been found as
an independent prognostic marker in a group of lymph node-
negative breast cancer patients (Silvestrini et al., 1993; Thor
et al., 1992).
Thus far, immunohistological evaluation of overexpression
of cyclin Dl in retrospective series has been hampered by
lack of antibodies detecting cyclin Dl in formalin-fixed,
paraffin-embedded tumour tissue. We affinity purified a
rabbit antiserum directed against human cyclin Dl, which
detects overexpression of cyclin Dl in formalin-fixed,
paraffin-embedded breast tumours. This antiserum was used
in a retrospective study of 248 breast cancer patients.
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Materials and methods
Tumour specimens
To assess clinicopathological associations, a consecutive
series of 248 patients registered between 1974 and 1982 with
operable breast cancer (clinical stage I-II) was studied. All
patients underwent a modified radical mastectomy at the
Netherlands Cancer Institute. Adjuvant therapy was admi-
nistered according to protocols, used at that time:
premenopausal patients with axillary lymph node metastases
received six cycles of CMF (cyclophosphamide, methotrexate
and fluorouracil). Complete follow-up data are available for
all patients. The median follow-up of the patients under
study was 106 months (ranging from 1 to 159), 68% (s.e. 3%)
being recurrence free after 5 years.
Tissues were fixed for at least 24 h in neutral buffered 4%
formaldehyde. After paraffin embedding, 5-um-thick sections
were cut and routinely stained with haemotoxylin and eosin.
All slides were reviewed by one pathologist (JP), tumours
were typed according to WHO (1981) criteria and invasive
ductal carcinomas were graded according to a modification of
Bloom and Richardson's method (Elston and Ellis, 1990).
For statistical reasons, grade II tumours were subdivided in
well to intermediately differentiated and intermediately to
poorly differentiated tumours, using the number of mitoses
and extent of tubule formation as criteria. Oestrogen receptor
(ER) status was determined routinely by the dextran-coated
charcoal assay on tumour cytosols. Receptor levels of
> 10 fmol mg-' of cytosolic protein were considered
positive.
Immunohistochemistry
The primary antibodies used for staining of sections were an
affinity-purified rabbit anti-cyclin Dl antibody (Michalides et
al., 1995) and a mouse monoclonal antibody detecting p53,
DO-7 (Dako). The affinity-purified rabbit polyclonal anti-
body was generated by injection of a P-galactosidase-cyclin
Dl fusion protein, using the carboxy-terminal part of cyclin
Dl (aa 217-296, corresponding with the NcoI-DdeI
fragment of cyclin Dl) into rabbits. Antibodies directed
against the cyclin Dl part of the fusion protein were affinity
purified on a GST-cyclin-Di fusion protein, using the whole
size cyclin Dl protein (corresponding with the NcoI-HindIII
fragment of cyclin Dl), coupled covalently to a CH-activated
Sepharose-4B (Pharmacia). With this procedure, antibodies
reactive to the P-galactosidase and (contaminating) bacterial
proteins were removed. In immunoprecipitation experiments,
the antibody was shown to be specific for cyclin DI
(Michalides et al., 1995), and did not cross-react with either
cyclin D2 or cyclin D3, since no immunostaining was found
with H9 cells, which express these members of the cyclin D
family, but not cyclin Dl (Lukas et al., 1994).
For immunohistochemistry, dewaxed and rehydrated
sections (on silane-coated slides) were covered with citrate
buffer (10 mM, pH 6) and underwent a microwave-retrieval
treatment (setting at 450 W) for 15 min (Greenwell et al.,
1991). The slides were then washed twice with phosphate-
buffered saline (PBS), and were rinsed thoroughly with PBS
between each of the following steps. The sections were first
blocked with undiluted swine serum (for staining of cyclin
DI) or rabbit serum (for staining of p53), for 10 min at 37°C.
The sections were then incubated overnight with a 1: 80
dilution of B31S affinity-purified rabbit-anti-cyclin Dl in
PBS/i % bovine serum albumin (BSA), or with a 1:400
dilution of DO-7 overnight at 4°C. Sections were then
incubated with biotinylated rabbit anti-mouse, or swine anti-
rabbit antiserum (1:1000 in PBS/I%BSA) (Dako) for 30 min
at room temperature. Preformed peroxidase-conjugated
streptavidin -biotin complex (Dako) was then applied for
30 min at room temperature, and peroxidase was demon-
strated by applying 0.05% diaminobenzidine containing 0.6%
hydrogen peroxide for 5 min. The samples were then
thoroughly washed in water, nuclei were lightly counter-
stained with haematoxylin, and sections were dehydrated and
mounted. For each of the antibodies, a corresponding tissue
section was incubated in PBS without the primary antibody
as a control for non-specific staining.
Statistical analyses
Associations between overexpression of cyclin DI or p53 and
clinicopathological variables were analysed using the chi-
square test or the Fisher test for discrete variables and the t-
test for continuous variables. Survival curves and disease-free
interval curves were calculated using the method of Kaplan
and Meier (1958). The statistical analyses of the differences
between the curves were performed using the stratified log-
rank test for censored data, with time to recurrence or death
as end points (Mantel, 1966). BMDP (release 1990; Statistical
Software) was used in all statistical analyses. P-values of <
0.05 were considered statistically significant.
Quantitative PCR
In order to associate the immunohistochemical overexpres-
sion of cyclin Dl with the degree of cyclin Dl DNA
amplification, we compared immunohistochemical staining
patterns of cyclin Dl with the degree of cyclin Dl
amplification as determined by quantitative PCR. There-
fore, high molecular weight DNA was isolated from frozen
tissue of breast tumours. Cryostat sections of these cases were
previously examined in order to determine the proportion of
normal and neoplastic tissue present in each sample. Tumour
samples were selected only if more than 75% of the cells
consisted of carcinoma. Quantitative PCR was performed
according to Frye et al. (1989), using cyclin Dl primer
combinations: 5'-GAAAGTAGGACCTCA-3', (nt 2335-
2350) and 5'-CCTGTCCTCCCT-3' (nt 2912-2901), yielding
a cyclin Dl DNA fragment of 577 nucleotides, and as control
PBGD (phorbobilinogen deaminase) primers 5'-ATGA-
GAGTGATTCGCGTGGGT-3' and 5'-TTTCAATGTTGC-
CACCACACT-3' (corresponding to cDNA positions 79-98
and 131-156 respectively), yielding a genomic PBGD
fragment of 430 nucleotides. Polymer chain reaction (PCR)
conditions were as follows: denaturation of the DNA at 94°C
for 1 min, annealing at 63°C for 30 s and transcription at
72°C for 2 min. PCR was performed using 2 mm magnesium
chloride for 24 cycles using 1 pCi of [X_-32P]dCTP (3000
Ci mmol-', Amersham) using increasing amounts of cellular
DNA. The 32P-labelled PCR-DNA products were analysed
on a 6% polyacrylamide gel. The gels were fixed in 10%
acetic acid, dried and exposed on Kodak X-ray films at
-70°C using intensifying screens. Quantitation of autoradio-
grams was performed by image analysis using a Cohu camera
(type 4712 with a 50 mm Nikkon lens) and the public domain
program NIH Image (Wayne, NIH), run on an Apple
Macintosh LCII. The ratio of intensities of the PCR-DNA
fragments of cyclin Dl and PBGD at non-saturating levels of
input cellular DNA was determined to indicate the degree of
cyclin Dl amplification.
Results
Immunohistochemical detection of overexpression of cyclin DI
The affinity-purified polyclonal antibody against cyclin DI,
B31S, detected a 33 kDa cyclin DI protein in immunopre-
cipitation experiments using cyclin DI-expressing cells
(Michalides et al., 1995). This antibody detected nuclear
staining of cyclin Dl in cyclin Dl-overexpressing cells, such
as MCF-7 and UMSCC2. This reactivity was removed after
preabsorption of the antibody with an excess of in vitro-
generated GST-cyclin Dl protein. The cyclin Dl protein was
not detected in H9 cells, which only express cyclin D2 and
D3, but not cyclin Dl (Lukas et al., 1994), and also not in
Saos cells expressing none of the known cyclin D proteins.
After microwave retrieval, B31S detected in formalin-fixed,
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Table I Correlation between cyclin Dl immunohistology and cyclin
Dl amplification
Tumour Cyclin Dl Cyclin D1
number staininga amplificationb
434 1
448 1
449 1
436 ++ 2
445 +/ 2
446 +1 2
407 + 3
472 + 3
394 + 4
498 + + 5
330 ++ 6
395 + + 10
aStaining results were graded as: + +, >50% of tumour cells
positive; +, 5 -50% of tumour cells positive; +/-, < 5% of tumour
cells positive; -, negative. bDegree ofamplification was determined by
quantitative PCR as described in Materials and methods.
paraffin-embedded tissue sections a nuclear staining in all
tumour specimens with a cyclin Dl amplification (Table I
and Figure 1). The staining was eliminated when the
antiserum was preabsorbed with an excess of in vitro-
synthesised GST-cyclin D1. Staining was found in the
nucleus, and tumour cells showed a range of intensities of
staining. None of the tumours examined showed only focal
areas of cyclin Dl staining. When a heterogeneous staining
was observed, this was present over the whole tumour area.
Only occasionally weak staining of some of the normal
mammary gland cells was observed. The variation in staining
in tumour sections might well be due to the cell cycle-
associated expressioh pattern of cyclin DI protein; this is
maintained in tumour cells with an overexpression of cyclin
Dl (Lukas et al., 1994). Despite this variation, straightfor-
ward gradation of the staining, depending on staining
intensity and percentage of nuclei staining could easily be
performed by three independent observers, + +, > 50% of
the nuclei positive with a strong intensity; +, 5-50% of the
tumour nuclei clearly positive; +/- less than 5% of the
tumour nuclei positive with weak intensity; and -, negative,
no staining at all. Examples of staining results are given in
Figure 1. Similar staining patterns have been reported in
methacarn-fixed tumours by others (Bartkova et al., 1994;
Gillett et al., 1994), using the monoclonal antibody DCS-6.
In order to correlate the immunohistochemical over-
expression of cyclin Dl with the degree of amplification, we
examined various breast tumours for cyclin Dl staining as
well as cyclin Dl amplification. The range of amplification of
the cyclin Dl gene varied from 1 to 10 in the 12 breast
tumour samples analysed, see Table I. With one exception,
tumour sample 436T, the immunohistological staining of the
corresponding tumour preparations, fixed in formalin and
embedded in paraffin, correlated with the degree of
amplification of cyclin Dl DNA. The one exception, 436T,
was previously shown to contain an overexpression of cyclin
Dl mRNA without concomitant cyclin Dl amplification
(Schuuring et al., 1992b). These results indicate that, in these
tumours, immunohistological staining of cyclin DI with
l
Figure 1 Immunohistochemical staining of cyclin Dl (a-e) and p53 (f) in primary breast tumours. (a) Strong, + + staining of a
lobular carcinoma T 81-8215, x 62.5. (b) Strong, + + staining of an intraductal carcinoma T 80-4200, x 62.5. (c) Negative
staining of a medullary carcinoma T 80-1120, x 62.5. (d) A moderate +/- staining of an intraductal carcinoma T 80-4205, x
62.5. (e) Strong, + + staining of an invasive ductal carcinoma T 82-722, x 50, with no staining of normal breast. (f) Strong, + +
staining on an invasive ductal carcinoma T 2631, x 250.
Iantiserum B31S corresponds to amplification. We stress,
however, that amplification levels as determined with
quantitative PCR, are not absolute, because of the
admixture of normal cells.
Immunohistochemical detection ofp53
Immunohistochemical detection of p53 was performed in a
similar way to cyclin Dl, but using monoclonal antibody
DO-7 (Ebina et al., 1994). Only clear nuclear staining of p53
was accounted for in this series. The grading of p53 staining
of the tumours was identical to the grading used for the
cyclin DI staining. This grading system has also been used
with this antiserum by others (Cornelis et al., 1994; Ebina et
al., 1994), and demonstrated a correlation between p53
mutation and nuclear overexpression of p53 (Cornelis et al.,
1994). An example of a + + staining of p53 is given in
Figure 1.
Association of overexpression of cyclin DI or p53 with
clinicopathological parameters
Overexpression of cyclin Dl occurred in 85/248 (= 34%),
and of p53 in 44/248 (= 18%) of the breast cancer cases.
Table II summarises the association of various clinicohisto-
logical parameters with overexpression of cyclin Dl or p53.
For these studies, we grouped the staining patterns + + and
+ together as positive, and + / - and - as negative, but
results did not differ when either subgroup was analysed
alone, or when + +, + and +/ - were taken together as a
positive group. Overexpression of cyclin DI was not
restricted to a particular stage of the disease, and no
significant associations were found with pT or pN stage.
Overexpression of cyclin Dl occurred more frequently in ER-
positive tumours, whereas p53 overexpression was associated
with ER-negative tumours. Overexpression of cyclin Dl did
not coincide with overexpression of p53 in the whole series of
breast cancers. p53 overexpression was more frequently
found in poorly differentiated tumour types, and was just
significantly (P = 0.049) associated with invasive ductal
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carcinoma. No associations with disease-free interval or
overall survival were found (Figure 2 and Table III).
Subgroup analysis of overexpression of either cyclin Dl or
p53 and disease-free interval in ER-positive and ER-negative
breast cancer patients revealed an opposite trend (Table IV).
In the ER-negative subgroup, the association between
overexpression of cyclin DI and disease-free interval reached
statistical significance (P= 0.02). This is, however, based on
small numbers (four out of six patients with overexpression
of cyclin DI showed recurrence, whereas only 16 out of 58
cyclin DI-negative cases did so). There was no association
between overexpression of cyclin Dl or p53 and disease-free
interval in either the lymph node-negative or lymph node-
positive subgroup.
The characteristic clinicopathological parameters for
breast cancer, such as number of positive lymph nodes, age
of the patients, tumour grade and pathological T and N
status, appeared to be significant prognostic marker for
disease-free interval and mortality in this group of breast
cases (Table III). In conclusion, overexpression of cyclin DI
and of p53 was of no apparent prognostic value.
Discussion
Overexpression of cyclin DI and prognosis
About 15-20% of breast tumours show amplification of the
cyclin Dl gene, and approximately 30-40% show over-
expression of either cyclin Dl mRNA (Buckley et al., 1993)
or protein (Gillett et al., 1994). The difference in frequency of
tumours with overexpression and amplification of cyclin DI
is attributed to deregulated cyclin Dl expression that is
independent of amplification (Schuuring et al., 1992b). Our
finding of 34% of the 248 breast tumours showing
overexpression of cyclin DI is in agreement with Gillett et
al. (1994). We also found a significant association between
overexpression of cyclin DI and ER positivity of breast
tumours (Borg et al., 1991; Schuuring et al., 1992a; Henry et
al., 1993). A difference, however, was found with respect to
the prognostic value of cyclin Dl. Previous studies indicated
Table II Association of known prognostic factors with overexpression of cyclin Dl and p53 in 248 patients with breast cancer
Cyclin Dl p53
Characteristics + +;+ +/-;- P-value + +;+ +/-;- P-value
Age (mean in years) 57.8 59.5 0.31 59.5 58.8 0.77
pTNM status
Tis 2 2 0 4
TI 37 61 14 84
T2 40 88 29 99
T3/T4 3 9 0.59 0 12 0.010
pNO 44 92 28 108
pNl 40 70 16 94
pN3 0 1 0.62 0 1 0.42
Histological grade
I/I-II 32 52 6 78
II -III/III 35 65 0.66 25 75 0.0013
Histological type
IDC 72 134 41 165
Non-IDC 13 29 0.62 3 39 0.049
Oestrogen receptor
Positive 61 72 12 121
Negative 6 58 0.0000 23 41 0.0000
DFS status
Alive NED 42 82 20 104
Recurrence 34 57 16 76
Dead NED 8 24 8 24
OS status
Alive 47 89 24 112
Dead 38 74 20 92
Tis, ductal carcinoma in situ; IDC, invasive ductal carcinoma; NED, no evidence ofdisease; DFS, disease-free survival; OS, overall survival; pN,
pathological lymph node status; pT, pathological tumour stage.Cyclin DI and p53 in breast cancer
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that amplification of chromosomal region 11q13, encompass-
ing cyclin Dl, is indicative of poor prognosis of breast cancer
(Borg et a!., 1991; Henry et al., 1993; Schuuring et al., 1992a;
Tsuda et al., 1989). This was, however, not confirmed in
another study (Lonn et al., 1994). Our study included a large
series of breast cancer patients with operability as the only
selection criterium. It is the first retrospective study
investigating overexpression of cyclin Dl protein as a
potential marker. Our results precluded overexpression of
cyclin Dl from being a prognostic marker for breast cancer.
Discrepancies with the other studies could be a result of the
following factors.
Composition of the tumour series The tumours studied here
are all of low stage. In other studies in which amplification of
DNA is evaluated by the Southern blotting technique, there
is inevitably a bias towards inclusion of larger tumours.
Treatment of patients also did not affect the results.
Hormonal treatment was only given to three patients; and
38 out of the 248 patients received chemotherapy. There
appeared to be no association between overexpression of
cyclin Dl and recurrence-free interval stratified by che-
motherapy (P = 0.2674).
Sensitivity of the methods The heterogeneous staining
pattern and the variation of staining intensities within one
tumour sample are most likely due to variation in the
amounts of cyclin Dl protein in the tumour cells, which is
a1)
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related to a cell cycle-associated expression pattern of cyclin
Dl protein. This is still present in tumours with an
overexpression of cyclin Dl (Lukas et al., 1994).
The data from Table I showed overexpression ofcyclin Dl
protein, graded as +, in tumours with an at least 3-fold
amplification of cyclin Dl DNA. This implies that some of
the normal mammary gland cells that were occassionally seen
as weakly positive might have expressed a low level of cyclin
Dl protein as is seen in tumours with a < 3-fold
amplification of cyclin Dl DNA. This would have been
scored as +/-, and in the statistical analysis these cases
would have been ranked in the negative group. One might
question the impact of a 2-fold amplification of cyclin Dl
DNA, or a +/- graded overexpression of cyclin Dl on
tumour prognosis. The statistical analysis of the data,
however, did not yield different results when the various
combinations of staining results (+ + alone vs +, +/-,
and -; or + +, +, and +/ - vs - alone) were considered.
We therefore, hold it unlikely that overexpression of cyclin
Dl as measured by immunohistochemistry would have been
less accurate than measuring amplification of cyclin Dl
DNA. In order to verify this point we will analyse a
previously reported large series of breast cancer patients
(Schuuring et a!., 1992a) for cyclin Dl overexpresssion as well
as for cyclin Dl DNA amplification. Data on cyclin Dl
DNA amplification of the series of breast tumours analysed
in this study are, unfortunately, not available.
Relevance of overexpression of cyclin DI We identified
previously two relevant genes on the 11ql3 amplicon, cyclin
Dl and EMS-1, both being consistently amplified and
overexpressed in breast tumours and squamous cell
carcinomas harbouring an 11q13 amplification, and in cell
lines derived from them (Schuuring et al., 1992b). Because of
the transforming ability of cyclin Dl, we assume that cyclin
Dl is the most relevant gene on this large amplicon. The very
large size of the amplicon, however, could also indicate that
co-expression of another gene confers a relative advantage to
these cells. In that case, an overexperssion of cyclin Dl
without concomitant amplification of the 11q13 region could
be irrelevant for tumour progression. In light of the recent
findings of cyclin Dl itself contributing to the transforma-
tion, we hold this possibility unlikely.
Of all these considerations, we hold the first possibility, an
inadvertent selection of breast cancer cases as a consequence
of using tumours that are applicable for Southern blotting,
the most likely one to explain discrepancies concerning the
prognostic value of amplification or overexpression of cyclin
Dl, but cannot formally exclude the other possibilities.
0 1 2 3 4 5 6 7 8 9 10 11 12 13
a
b
Positive 16/44
---- Negative 76/204
2 Log-rankX
=0.044,P=NS
Figure 2 Disease-free interval curves for patient groups with and
without overexpression of cyclin DI (a) and p53 (b).
Overexpression of cyclin DI and clinicopathological
parameters
We found a significant association between overexpression of
cyclin Dl and ER positivity (Table II), which was previously
reported for cyclin Dl amplification (Borg et a!., 1991; Fantl
et a!., 1990; Henry et al., 1993). This significant association
with overexpression of cyclin Dl suggests a direct relation-
ship. It might well be that oestrogen-responsive breast
tumours show an overexpression of cyclin Dl as a result of
cyclin Dl induction by oestrogen. This has been reported for
T47D cells, an oestrogen-dependent breast tumour cell line
(Mushgrove et a!., 1993; Buckley et a!., 1993). The significant
association between ER positivity and cyclin Dl over-
expression renders overexpression of cyclin Dl by itself
unlikely as a prognostic marker, unless a subgroup of ER-
positive cases with an increased risk of recurrence had been
identified. Our findings (Table IV) do not support this
hypothesis. Overexpression of cyclin Dl, which is the result
of enhanced sensitivity to oestrogen in ER-positive tumours,
but not of amplification of cyclin Dl DNA, could affect the
risk of evaluation only when such an overexpression is
without further consequence. This is to be analysed in the
previously mentioned breast cancer series.
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Table HI Association between potential prognostic factors and disease-free inter-al (DFI) and overall survival (OS) in 248 breast cancer
patients log-rank P-value)
DFI OS
Recurrence No Dead
Characteristics recurrence P-value 4.5% Alive P-value
Age (mean in years) 59.9 57.3 0.2207a 61.6 56.8 0.0042
pTNM status
Tis 0 4 0 4
TI 32 66 36 62
T2 48 80 64 64
T3 T4 10 2 0.0002 10 2 0.0009
pN0 36 100 50 86
pNl pN3 56 55 0.0000 61 50 0.00"3
Histological arade
I I-II 26 58 32 52
II-III III 50 50 0.0034 59 41 0.0011
Histological type
IDC 78 128 94 112
Non-IDC 14 28 0.4521 18 24 0.58990
Oestrogen receptor
Positive 57 76 65 68
Nezative 0 44 0.1860 25 39 0.3405
Cvclin Dl
--.- .LO 50 38 47
- -.- 57 106 0.2687 74 89 0.8842
p53
16 28 20 24
- -.- 76 128 0.8340 91 112 0.9877
aGlobal Chi-square P-value from Cox proportional hazard analysis. For abbreviations used. see Table II.
Table IV Association of overexpression of cyclin DI and p53 with
disease-free interval (DFI) in subgroups of 248 patients with breast
cancer
Log-rank
Subgroup n I ariable P-value
ER positive 133 p53 0.21
C%-clin D1 0.44
ER negative 64 p53 0.81
Cvchin D1 0.02
pN0 136 p53 0.76
CN-clin D1 0.30
pN1 -3 111 p53 0.52
Cvcin D1 0.68
ER. oestrogen receptor.
Oierexpression ofp53
Overexpression of p53 was included in this study for
comparison of our series of patients with others. Positive
immunohistochemical staining of p53 is generally accepted to
reflect the presence of mutated p53 (Harris and Hollstein.
1993: Levine et al.. 1994). because many mutant proteins
have greatly expanded half-lives. Immunohistochemical
detection of overexpression of p53. using monoclonal
antibody. DO-7 and evaluating only nuclear staining
pattern, correlated significantly with mutation in the p53
gene (Cornelis et al.. 1994: Ebina et al.. 1994). Using strict
criteria. we found 180o of the 248 breast tumour cases to be
positive. which is within the range reported by others
(Cornelis et al.. 1994: Thor et al.. 1992). The statistically
significant associations between p53 overexpression and
clinical parameters such as tumour size. histological grade.
and ER negativitv. were also found by others (Faille et al..
1994: Marchetti et al.. 1993; Thor et al.. 1992). By these
criteria. our series does not deviate from other tumour series.
No association was found with disease-free interval. also not
in the ER-negative or lymph node-negative or -positive
subgroups of these 248 breast tumours cases. In this aspect.
our series differs from others. in which such an association
was found (Silvestrini et al.. 1993: Thor et al.. 1992). In those
studies. overexpression of p53 occurred more frequently in
tumours with clinical metastases at time of presentation.
Since patients with clinical metastases are not included at all
in our study. we argue that p53 overexpression is not
indicative of prognosis in the group of breast cancer cases
that entered this study. i.e. a group selected only for surgical
resection. without distant metastasis and with relatively small
tumour size.
Overexpression of p53 occurs in the earliest recognised
phase of breast cancer. is maintained during breast tumour
progression (Davidoff et al.. 1991) and appears to be
associated with large tumours and with metastases at time
of presentation (Faille et al.. 1994: Thor et al.. 1992). Since
such tumours were not included in our study. this would
support the notion that p53 overexpression could be a
marker for prognosis when no selection of patients is applied
at all. but would remain unnoticed in a selected group of
patients still eligible for adjuvant therapy. This could also
apply for overexpression of cyclin Dl.
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